Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral version of the booming class of drugs ...

Eli Lilly says it plans to submit orforglipron to the U.S. Food and Drug Administration for approval as a Type 2 diabetes treatment ... have to have the healthy diet and exercise." ...

Eli Lilly reported. Related FDA warns of fake Ozempic Type 2 diabetes injection drugs Additives in diet drinks, processed foods may raise type 2 diabetes risk, study says Vitamin deficiencies ...

Lilly said its new pill would continue the company's "mission to reduce chronic diseases like type 2 diabetes," which it says is expected to roughly impact 760 million adults by 2050. During the ...

Drug manufacturer Eli Lilly announced ... loss this year and diabetes in 2026. The FDA’s review could take months, yet analysts speculate that if things go to plan, orforglipron could be made ...

Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday ... and "inadequate glycemic control with diet and exercise alone." ...

Eli Lilly And Co LLY on Thursday reported ... compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. In the first Phase 3 trial of ...

Eli Lilly & Co.’s stock soared 14% Thursday ... results from a late-stage trial of a GLP-1 treatment for Type 2 diabetes and obesity in pill form. The last time the stock rose as much was ...

Ozempic, approved for diabetes in 2017, is designed to target an intestinal hormone called GLP-1. It competes with Lilly's injectable tirzepatide — sold under the brand names Mounjaro for ...

The trial is one of several that Lilly is running to test the drug, called orforglipron, in diabetes, obesity and other related conditions like sleep apnea. Investors and analysts had expected it ...

Eli Lilly says it plans to submit orforglipron to the U.S. Food and Drug Administration for approval as a Type 2 diabetes treatment in 2026. For weight management, it plans to submit the drug to ...